PTGS2 and inflammatory bowel disease: Thus, in independent BLT models and unlike ART and consistently with our prior data that apoA-I mimetic peptide reduce proinflammatory bioactive lipids and aberrant COX-2 activity in mouse models of inflammatory bowel disease [11], Tg6F therapy for up to 14 weeks attenuated HIV-induced increases in plasma and gut biolipids and intestinal COX-2 protein levels.